FOLH1 and prostate cancer: While no quantitative threshold exists to discriminate between causes of PSMA uptake [41], the relatively mild PSMA uptake demonstrated by metastatic MCC compared to the higher PSMA uptake demonstrated by prostate cancer metastases we observed is concordant with the typical patterns of nonprostatic uptake others have reported [8, 37].